Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 241 AL 255

Battling Parkinson's and Alzheimer's: The Neuroprotective Power of Carnosic Acid

Goyal A, Verma A, Kumari A, Mishra MK.

J Biochem Mol Toxicol. 2026 Jul;40(7):e70991. doi: 10.1002/jbt.70991.

From plastics to pathology: The neurodegenerative impact of Bisphenol-A on Alzheimer's disease

Kumari S, Dhapola R, Sharma P, Paidlewar M, Vellingiri B, Cho SG, Dayem AA, Medhi B, Harikrishnareddy D.

Ageing Res Rev. 2026 Aug;120:103219. doi: 10.1016/j.arr.2026.103219. Epub 2026 Jun 25.

The Role of Sphingosine-1-Phosphate Signaling in Cerebral Ischemia/Reperfusion Injury and Alzheimer's Disease Pathology

Czubowicz K, Motyl JA, Wencel A, Strosznajder RP.

Int J Mol Sci. 2026 Jun 9;27(12):5200. doi: 10.3390/ijms27125200.

Advances in 3D cell culture models for alzheimer's disease drug discovery

Valdivia-Aviña K, Ochoa-Hugo SE, Hernández-Sapiéns MA, Canales-Aguirre AA.

Expert Opin Drug Discov. 2026 Jul;21(7):761-777. doi: 10.1080/17460441.2026.2691833. Epub 2026 Jun 27.

HDAC3 in Alzheimer's Disease: established evidence, unresolved questions, and translational priorities

Luo J, Wu X, Jiang D, He G, Du Y.

Mol Biol Rep. 2026 Jun 27;53(1):1017. doi: 10.1007/s11033-026-12213-y.

The interplay between gut microbiota and Alzheimer's disease: mechanistic insights from dysbiosis to disease modulation

Das K, Khatun R, Begum S, Bhattacharyya K, Datta M, Saha D, Sarma A, Mehta P, Das BK.

Metab Brain Dis. 2026 Jun 30;41(1):149. doi: 10.1007/s11011-026-01922-9.

Brain Endothelial Glycocalyx as a Blood-Facing Translational Interface in Alzheimer's Disease: Beyond "Leaky" Barriers Toward Repair-First Stratification

Zhang C, Fang D, Zhang L.

Drug Des Devel Ther. 2026 Jun 26;20:619901. doi: 10.2147/DDDT.S619901. eCollection 2026.

Calibrating microglia states in Alzheimer's disease: decoding immune-metabolic networks and nano-targeted multicomponent therapies

Xing JF, Mu K, Yan X, Yang X, Zhang D, Gao W, Zhang T, Yang S, Wang R, Zhang W, Zhu Y.

Front Immunol. 2026 Jun 16;17:1843978. doi: 10.3389/fimmu.2026.1843978. eCollection 2026.

Comparison of ABBV-552 Safety and Pharmacokinetics in Healthy Asian and Western Adults

Miles N, McNamee B, Zadikoff C, Boiser J, Shebley M, Boinpally R.

Clin Pharmacol Drug Dev. 2026 Jul;15(7):e70072. doi: 10.1002/cpdd.70072.

Exercise and fluoxetine in Alzheimer's disease: Molecular mechanisms of synergistic and antagonistic effects (Review)

Wu M, Li Y.

Int J Mol Med. 2026 Sep;58(3):237. doi: 10.3892/ijmm.2026.5908. Epub 2026 Jul 3.

Targeting PARP1-dependent parthanatos in Alzheimer's disease: Mechanisms and therapeutic opportunities

Alameen AAM, Al-Kuraishy HM, Abdelaziz AM, Al-Gareeb AI, Albuhadily AK, Batiha GE.

Life Sci. 2026 Oct 1;402:124578. doi: 10.1016/j.lfs.2026.124578. Epub 2026 Jul 7.

Recent advances in Alzheimer's disease: From molecular mechanisms to therapeutic strategies

Rudman MD, Ulrich JD, Holtzman DM.

Cell. 2026 Jul 9;189(14):4193-4224. doi: 10.1016/j.cell.2026.06.006.

Synaptic dysfunction as a major driver in Alzheimer's disease: Beyond the amyloid paradigm

Mierzwa N, Wężyk M.

Neurosci Biobehav Rev. 2026 Oct;189:106858. doi: 10.1016/j.neubiorev.2026.106858. Epub 2026 Jul 9.

Attitudes of specialist memory-clinic patients with early symptomatic Alzheimer's disease towards lecanemab: results from a multicenter survey in Europe

Vöglein J, Levin J, Stögmann E, Haass C, Höglinger GU, Frölich L, Jessen F.

Sci Rep. 2026 Jul 9;16(1):21414. doi: 10.1038/s41598-026-61640-1.

Targeting the APOE4-driven peripheral-central immune axis: A new frontier for Alzheimer's disease therapy

Shang Y, Zhai Z, Cong L, Dong X.

Pharmacol Res. 2026 Sep;231:108339. doi: 10.1016/j.phrs.2026.108339. Epub 2026 Jul 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias